Implications of Serum Pepsinogen I in Early Endoscopic Diagnosis of Gastric Cancer and Dysplasia

References

• Hoel DG, Davis DL, Miller AB, Sondik EJ, Swerdlow AJ. Trends in cancer mortality in 15 industrialised countries, 19691986. J Natl Cancer Inst 1992;84: 313–20.
   Google Scholar
• Varis K. Surveillance of pernicious anaemia. In: Sherlock P, Morson BC, Barbara L, Veronesi U, editors. Precancerous lesions of the gastrointestinal tract. New York: Raven Press; 1983. p. 189–94.
   Google Scholar
• Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173–7.
   Google Scholar
• Varis K, Samloff IM, Ihamaki T, Siurala M. An appraisal of tests for severe atrophic gastritis in relatives of patients with pernicious anemia. Dig Dis Sci 1979;24:187–91.
   PubMed Web of Science ®Google Scholar
• The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.
   Google Scholar
• The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994;4:1–10.
   Google Scholar
• Varis K, Taylor PR, Sipponen P, Samloff IM, Heinonen OP, Albanes D, et al, for the Helsinki Study Group. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta carotene. Scand J Gastroenterol 1998;33:294–300.
   Google Scholar
• Samloff IM. Pepsinogens I and II. Purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1982;82:26–33.
   Google Scholar
• Tamm A, Villako K, Härkönen M, Karonen S-L. Serum pepsinogen I and the state of gastric mucosa in an Estonian population sample. Scand J Gastroenterol 1984;19:1091–4.
   Google Scholar
• Price AB. The Sydney system: histological division. J Gastroenterol Hepatol 1991;6:209–22.
   PubMed Web of Science ®Google Scholar
• Cuello C, Correa P, Zarama G, Lopez J, Murray J, Cordillo G. Histopathology of gastric dysplasias. Am J Surg Pathol 1979;3:491–500.
   PubMed Web of Science ®Google Scholar
• Morson BC, Sobin LH, Grundmann E, Johansen AA, Nagayo T, Serck-Hanssen A. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 1980;33:711–21.
   Google Scholar
• Jass JR. A classification of gastric dysplasia. Histopathology 1983;7:181–93.
   PubMed Web of Science ®Google Scholar
• Ming SC, Bajtai A, Correa P, Elster K, Järvi OH, Munoz N, et al. Gastric dysplasia: significance and pathologic criteria. Cancer 1984;54:1794–801.
   Google Scholar
• Sipponen P. Gastric dysplasia. In: Williams GT, editor. Gastrointestinal pathology. Berlin: Springer Verlag; 1990. p. 61–76.
   Google Scholar
• Varis K, Kekki M, Härkönen M, Sipponen P, Samloff IM. Serum pepsinogen I and serum gastrin in screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol 1991;186:117–23.
   Google Scholar
• Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengels K, et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 1996;73:819–24.
   PubMed Web of Science ®Google Scholar
• Borch K, Axelsson CK, Halgreen H, Damkjaer Nielsen MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 1989;24:870–6.
   Google Scholar
• Kokkola A, Haapiainen R, Laxén F, Puolakkainen P, Kivilaakso E, Virtamo J, et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow-up study. J Clin Pathol 1996;49:979–84.
   Google Scholar
• Farinati F, Rugge M, Di Mario F, Valiante F, Baffa R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients: a prospective study. Endoscopy 1993;25:261–4.
   Google Scholar
• Lansdown M, Quirke P, Dixon MF, Axon ATR, Johnston D. High grade dysplasia of the gastric mucosa: marker for gastric carcinoma. Gut 1990;31:977–83.
   Google Scholar
• Di Gregorio C, Morandi P, Fante R, De Gaetani C. Gastric dysplasia. A follow-up study. Am J Gastroenterol 1993;88:1714–9.
   PubMed Web of Science ®Google Scholar
• Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet 1997;349:1725–9.
   PubMed Web of Science ®Google Scholar
• Keyriläinen O, Sipponen P. Gastroskopia hyödyllinen tutkimus terveyskeskuksessa. Suomen Lääkärilehti 1997;52:4127–36.
   Google Scholar
• Heikkinen M, Pikkarainen P, Takala J, Räsänen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995;30:519–23.
   Google Scholar
• Miki K, Ichinose M, Yahagi N, Suzuki T, Oka M, Shimizu Y, et al. Efficiency of gastric screening system using serum pepsinogen test. 2nd International Gastric Cancer Congress. Munich, Germany, 27–30 April 1997.
   Google Scholar
• Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998;93:1090–6.
   PubMed Web of Science ®Google Scholar
• Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086–90.
   PubMedGoogle Scholar
• Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Tanka S, et al. The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. Hiroshima J Med Sci 1997;46:81–6.
   PubMedGoogle Scholar
• Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987;22:133–41.
   PubMedGoogle Scholar
• Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995;86: 1210–5.
   PubMedGoogle Scholar
• Kodoi A, Yoshihara M, Sumii K, Haruma K, Kajiyama G. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 1995;30:452–60.
   Google Scholar
• Aoki K, Misumi J, Kimura T, Zhao W, Xie T. Evaluation of cutoff levels for screening of gastric cancer using serum pepsinogens and distribution of levels of serum pepsinogen I, II and of PG1/PGII ratios in a gastric cancer case–control study. J Epidemiol 1997;7: 143–51.
   Google Scholar
• Kikuchi S, Wada O, Miki K, Nakajima T, Nishi T, Kobayashi O, et al. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research group on prevention of gastric carcinoma among young adults. Cancer 1994;73:2695–702.
   Google Scholar
• Farinati F, Di Mario F, Plebani M, Cielo R, Fanton MC, Valiante F, et al. Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer. Ital J Gastroenterol 1991;23:194–6.
   PubMedGoogle Scholar
• Nomura AM, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med 1980;93:537–40.
   PubMed Web of Science ®Google Scholar
• Hallissey MT, Dunn JA, Fielding JW. Evaluation of pepsinogen A and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions. Scand J Gastroenterol 1994;29: 1129–34.
   Google Scholar